Esthesioneuroblastoma: The Johns Hopkins experience

Vicente A. Resto, David W. Eisele, Arlene Forastiere, Marianna Zahurak, Ding Jen Lee, William H. Westra

Research output: Contribution to journalArticlepeer-review

148 Scopus citations


Background. Esthesioneuroblastoma (ENB) is an uncommon malignant neoplasm of the upper nasal cavity. Therapeutic management approaches for this neoplasm lack uniformity and there is no universally accepted staging system. Methods. A retrospective review of 27 patients with histologically confirmed ENB managed at The Johns Hopkins Hospital. Results. Eighty-five percent of patients had surgical resection as part of their disease management. Complete surgical resection was achieved in 62% of patients who had a craniofacial resection. Eighty percent of patients with negative surgical margins remain with no evidence of disease, with a median follow-up of 5.6 years. Adjuvant radiation therapy was beneficial to 62% of patients with positive surgical margins. Clinical responses were observed with cisplatin- and etoposide-containing chemotherapy regimens in patients with advanced disease. A revised staging system based on our experience is proposed. Conclusions. ENB is best managed by craniofacial resection with complete tumor resection. Adjuvant radiation therapy is warranted in patients that remain with positive histologic margins of resection. Chemotherapy with cisplatin- and etoposide-containing regimens may be useful for palliation of advanced disease. (C) 2000 John Wiley and Sons, Inc.

Original languageEnglish (US)
Pages (from-to)550-558
Number of pages9
JournalHead and Neck
Issue number6
StatePublished - 2000
Externally publishedYes


  • Chemotherapy
  • Craniofacial resection
  • Esthesioneuroblastoma
  • Radiation therapy
  • Tumor staging

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'Esthesioneuroblastoma: The Johns Hopkins experience'. Together they form a unique fingerprint.

Cite this